Amylyx Pharmaceuticals CEO Executes Significant Stock Sale Amid Ongoing Investigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Executive Stock Transaction: Joshua B Cohen, Co-CEO of Amylyx Pharmaceuticals, exercised 200,000 stock options and sold 138,167 shares between January 15 and 16, 2026, totaling approximately $1.9 million, highlighting significant financial activity within the company.
- Ownership Stake Change: This transaction reduced Cohen's direct holdings by 3.93%, leaving him with 3,379,465 shares, which equates to an insider ownership stake of 4.07%, potentially impacting market perceptions of his confidence in the company.
- Company Performance Review: Despite ongoing investigations, Amylyx experienced a strong year in 2025 with a stock price increase of approximately 223%, and its flagship therapy AMX0035 has shown effectiveness in slowing ALS progression, bolstering investor confidence.
- Potential Risk Factors: The company is currently under investigation by multiple law firms for alleged breaches of fiduciary duties by its directors and officers, and while business operations are performing well, investors should monitor how the investigation may affect the company's future prospects.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like AMLX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on AMLX
Wall Street analysts forecast AMLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMLX is 20.14 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.850
Low
15.00
Averages
20.14
High
25.00
Current: 14.850
Low
15.00
Averages
20.14
High
25.00
About AMLX
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Joshua B Cohen Sells 138,167 Shares for $1.9 Million
- Transaction Overview: On January 15 and 16, 2026, Joshua B Cohen sold 138,167 shares for approximately $1.9 million at a weighted average price of $13.59 per share, reducing his direct holdings to 3,379,465 shares, indicating a strategic adjustment in his ownership stake.
- Options Exercise Details: During the same period, Cohen exercised 200,000 stock options, reflecting his active participation in the company's equity incentive plan; however, the sales were primarily to cover option costs and tax obligations rather than discretionary investment decisions.
- Company Performance Review: Despite a significant drop post-2022 IPO, Amylyx Pharmaceuticals rebounded strongly in 2025 with a 223% stock price increase, highlighting its potential in treating neurodegenerative diseases, particularly with the success of its flagship product AMX0035.
- Legal Investigation Risks: Amylyx is currently under investigation by multiple law firms for alleged breaches of fiduciary duties by its directors and officers; while the company is performing well operationally, this legal risk could impact investor confidence, necessitating close monitoring of the investigation's developments.
Continue Reading
Amylyx Pharmaceuticals CEO Executes Significant Stock Sale Amid Ongoing Investigation
- Executive Stock Transaction: Joshua B Cohen, Co-CEO of Amylyx Pharmaceuticals, exercised 200,000 stock options and sold 138,167 shares between January 15 and 16, 2026, totaling approximately $1.9 million, highlighting significant financial activity within the company.
- Ownership Stake Change: This transaction reduced Cohen's direct holdings by 3.93%, leaving him with 3,379,465 shares, which equates to an insider ownership stake of 4.07%, potentially impacting market perceptions of his confidence in the company.
- Company Performance Review: Despite ongoing investigations, Amylyx experienced a strong year in 2025 with a stock price increase of approximately 223%, and its flagship therapy AMX0035 has shown effectiveness in slowing ALS progression, bolstering investor confidence.
- Potential Risk Factors: The company is currently under investigation by multiple law firms for alleged breaches of fiduciary duties by its directors and officers, and while business operations are performing well, investors should monitor how the investigation may affect the company's future prospects.
Continue Reading